HMC
Harvard Management Company Portfolio holdings
AUM
$1.44B
This Quarter Return
+10.11%
1 Year Return
+33.17%
3 Year Return
+230.83%
5 Year Return
+163.57%
10 Year Return
+194.2%
AUM
$1.84B
AUM Growth
+$1.84B
(+1.4%)
Cap. Flow
-$214M
Cap. Flow
% of AUM
-11.59%
Top 10 Holdings %
Top 10 Hldgs %
90.94%
Holding
34
New
10
Increased
1
Reduced
6
Closed
4
Top Buys
| 1 |
Salesforce
CRM
|
$206M |
| 2 |
Microsoft
MSFT
|
$183M |
| 3 |
AbCellera Biologics
ABCL
|
$165M |
| 4 |
Praxis Precision Medicines
PRAX
|
$43.6M |
| 5 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
$19.8M |
Top Sells
| 1 |
Alphabet (Google) Class A
GOOGL
|
$229M |
| 2 |
Palo Alto Networks
PANW
|
$199M |
| 3 |
Meta Platforms (Facebook)
META
|
$186M |
| 4 |
Intercontinental Exchange
ICE
|
$116M |
| 5 |
Uber
UBER
|
$99.3M |
Sector Composition
| 1 | Healthcare | 58.26% |
| 2 | Technology | 24.36% |
| 3 | Consumer Discretionary | 6.03% |
| 4 | Communication Services | 6.02% |
| 5 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Royalty Pharma
RPRX
$15.6B
| $735M | 39.88% | 14,690,780 | – | – |
|
|
2
Salesforce
CRM
$245B
| $206M | 11.2% | +927,541 | New | +$206M |
|
|
3
Microsoft
MSFT
$3.77T
| $183M | 9.91% | +821,062 | New | +$183M |
|
|
4
AbCellera Biologics
ABCL
$1.25B
| $165M | 8.96% | +4,105,095 | New | +$165M |
|
5
Light & Wonder
LNW
$7.76B
| $111M | 6.03% | 2,678,571 | – | – |
|
|
6
Meta Platforms (Facebook)
META
$1.86T
| $111M | 6.02% | 406,540 -681,093 | -63% | -$186M |
|
|
7
Palo Alto Networks
PANW
$127B
| $59.4M | 3.22% | 167,202 -559,019 | -77% | -$199M |
|
|
8
Praxis Precision Medicines
PRAX
$958M
| $43.6M | 2.37% | +792,617 | New | +$43.6M |
|
9
Invesco QQQ Trust
QQQ
$364B
| $35.4M | 1.92% | 112,765 -497 | -0.4% | -$156K |
|
10
Revolution Medicines
RVMD
$7.1B
| $26.5M | 1.44% | 670,382 | – | – |
|
11
iShares Core S&P 500 ETF
IVV
$662B
| $24.3M | 1.32% | 64,672 | – | – |
|
12
Relay Therapeutics
RLAY
$619M
| $22.5M | 1.22% | 541,124 | – | – |
|
|
KNTE
13
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $19.8M | 1.07% | +498,001 | New | +$19.8M |
|
14
SPDR Gold Trust
GLD
$107B
| $17.2M | 0.93% | 96,619 -22,395 | -19% | -$3.99M |
|
15
Generation Bio
GBIO
$40.4M
| $14.8M | 0.8% | 521,460 +15,187 | +3% | +$431K |
|
16
Pliant Therapeutics
PLRX
$101M
| $12.8M | 0.69% | 562,379 | – | – |
|
17
Nurix Therapeutics
NRIX
$714M
| $10.3M | 0.56% | 314,762 | – | – |
|
18
Vanguard FTSE Developed Markets ETF
VEA
$171B
| $8.22M | 0.45% | 174,041 | – | – |
|
|
NCNA
19
NuCana
NCNA
$6.09M
| $7.54M | 0.41% | 1,678,239 -641,541 | -28% | -$2.88M |
|
20
Fulcrum Therapeutics
FULC
$351M
| $4.81M | 0.26% | 410,714 | – | – |
|
21
iShares Core S&P Small-Cap ETF
IJR
$85.2B
| $4.57M | 0.25% | 49,710 | – | – |
|
22
Vanguard FTSE Emerging Markets ETF
VWO
$96.4B
| $4.03M | 0.22% | 80,360 | – | – |
|
23
iShares Core S&P Mid-Cap ETF
IJH
$100B
| $3.74M | 0.2% | 16,255 -2,289 | -12% | -$526K |
|
24
Seres Therapeutics
MCRB
$166M
| $3.23M | 0.18% | +131,847 | New | +$3.23M |
|
|
FSDC
25
DELISTED
FS Development Corp. Class A Common Stock
FSDC
| $2.75M | 0.15% | +250,000 | New | +$2.75M |
|